Snowden Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-5,889
| Closed | -$200K | – | 1217 |
|
|
2025
Q1 | $200K | Buy |
+5,889
| New | +$200K | 0.01% | 1162 |
|
|
2024
Q4 | – | Sell |
-9,818
| Closed | -$461K | – | 1220 |
|
|
2024
Q3 | $461K | Buy |
9,818
+36
| +0.4% | +$1.69K | 0.01% | 811 |
|
|
2024
Q2 | $528K | Buy |
9,782
+237
| +2% | +$12.8K | 0.02% | 727 |
|
|
2024
Q1 | $651K | Buy |
9,545
+3,412
| +56% | +$233K | 0.02% | 646 |
|
|
2023
Q4 | $384K | Buy |
6,133
+668
| +12% | +$41.8K | 0.01% | 817 |
|
|
2023
Q3 | $248K | Sell |
5,465
-347
| -6% | -$15.8K | 0.01% | 924 |
|
|
2023
Q2 | $326K | Hold |
5,812
| – | – | 0.01% | 922 |
|
|
2023
Q1 | $263K | Sell |
5,812
-778
| -12% | -$35.2K | 0.01% | 988 |
|
|
2022
Q4 | $268K | Sell |
6,590
-25
| -0.4% | -$1.02K | 0.01% | 964 |
|
|
2022
Q3 | $432K | Sell |
6,615
-993
| -13% | -$64.8K | 0.02% | 708 |
|
|
2022
Q2 | $462K | Sell |
7,608
-854
| -10% | -$51.9K | 0.02% | 667 |
|
|
2022
Q1 | $531K | Sell |
8,462
-1,043
| -11% | -$65.4K | 0.02% | 614 |
|
|
2021
Q4 | $720K | Sell |
9,505
-4,179
| -31% | -$317K | 0.04% | 386 |
|
|
2021
Q3 | $1.53M | Buy |
13,684
+437
| +3% | +$48.9K | 0.08% | 299 |
|
|
2021
Q2 | $2.14M | Sell |
13,247
-5,468
| -29% | -$885K | 0.11% | 250 |
|
|
2021
Q1 | $2.28M | Buy |
18,715
+2,323
| +14% | +$283K | 0.13% | 218 |
|
|
2020
Q4 | $2.51M | Buy |
+16,392
| New | +$2.51M | 0.17% | 183 |
|